Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Lilly’s Ultra-Fast Acting Insulin Lyumjev Now Available in Japan
June 18, 2020
- Kyowa Kirin Commits Up to US$10 Million in 4BIO Venture Fund, Its 1st VC Investment
June 18, 2020
- Takeda Out-Licenses 7 Psych Programs to Neurocrine
June 18, 2020
- Canada OKs Sunovion’s Apomorphine Sublingual Film for Parkinson’s
June 17, 2020
- 10 Foreign Makers in Japan Grow Above Market with 5.5% Sales Rise in 2019
June 17, 2020
- Distributors See 800 Item Shortages as Good Guesstimate as They Share Off-Year Survey Concerns with Chuikyo Wholesaler Rep
June 17, 2020
- Astellas Relaxes Commuting Rate Limit to 50% at HQ as COVID-19 Situation Improves
June 17, 2020
- Oncolys Inks US$300 Million-Plus Pact for OBP-601; Potential for Neurodegenerative Diseases Eyed
June 16, 2020
- Meiji/Solasia Plan Japan NDA for PTCL Med in First Half of 2021
June 16, 2020
- Taiho Files Aloxi for Pediatric Use
June 16, 2020
- Poteligeo Now Available in Germany: Kyowa Kirin
June 16, 2020
- Mitsubishi Tanabe Launches PIII Dersimelagon Study for Rare Protoporphyria, Targeting US Filing in FY2021
June 16, 2020
- Kaken’s Axillary Hyperhidrosis Treatment Hits Primary Goal in Japan PIII Study
June 16, 2020
- 26 Japan Drug Makers Generate 56.4% of Sales Overseas in FY2019, Shire Buy Gives Boost: Tally
June 15, 2020
- Otsuka’s ADHD Med Hits Primary Goal in US PIII Trials
June 15, 2020
- Takeda, Mitsubishi-UBS Asset JV to Collaborate in Shonan iPark Operations
June 15, 2020
- PeptiDream, US Merck Link Up to Develop COVID-19 Treatment
June 15, 2020
- Daiichi Sankyo to Kickstart COVID-19 Vaccine Development
June 15, 2020
- AbbVie Files Rinvoq for Psoriatic Arthritis in Japan
June 15, 2020
- Takeda to Divest 18 Non-Core Meds in Asia-Pacific to Celltrion for US$278 Million
June 12, 2020
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…